Pancreatic resection with perioperative drug repurposing of propranolol and etodolac: trial protocol of the phase-II randomised placebo controlled PROSPER trial

INTRODUCTION: Pancreatic cancer is the fourth-leading cause of cancer-related death in developed countries. Despite advances in systemic chemotherapy, the mainstay of curative therapy for non-metastatic disease is surgical resection. However, the perioperative period is characterised by stress and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Hüttner, Felix J, Rooman, Ilse, Bouche, Gauthier, Knebel, Phillip, Hüsing, Johannes, Mihaljevic, André L, Hackert, Thilo, Strobel, Oliver, Büchler, Markus W, Diener, Markus K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528424/
https://www.ncbi.nlm.nih.gov/pubmed/32998931
http://dx.doi.org/10.1136/bmjopen-2020-040406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528424/
https://www.ncbi.nlm.nih.gov/pubmed/32998931
http://dx.doi.org/10.1136/bmjopen-2020-040406

Ejemplares similares